Physician

Aaron David Crookshank, MD

According to 2025 Medicare claims, Aaron Crookshank, MD (NPI: 1285875633) practices pulmonary disease in the Camden, NJ market, with the plurality of this provider's patient population coming from Camden, NJ. This provider's primary affiliated billing organization is VIRTUA MEDICAL GROUP, PA (NPI: 1649226515; TIN: 271348772) and primary practice location at 08053-4145.

Crookshank's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 816 traditional Medicare patients, billed 2,072 HCPCS/CPT codes, and received $194,143 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,582 prescription claims across 484 beneficiaries totaling $1,562,314 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 4,068 claims. Open Payments data shows 91 records totaling $1,714. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $118,766 to $1,562,314. For DME billing, reported payments rose steadily, from $135,250 to $207,500.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,507	3,438	$268,343
2016	1,282	3,367	$310,824
2017	1,242	3,452	$272,911
2018	1,209	3,598	$279,292
2019	1,114	3,689	$253,032
2020	950	2,475	$242,991
2021	920	2,346	$220,222
2022	887	2,224	$211,488
2023	905	2,160	$200,730
2024	816	2,072	$194,143

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	110	513	$118,766
2016	114	515	$104,149
2017	132	581	$244,684
2018	192	1,021	$625,684
2019	233	1,258	$674,022
2020	201	1,316	$631,604
2021	227	1,559	$923,689
2022	299	1,826	$793,828
2023	375	2,649	$1,249,297
2024	484	3,582	$1,562,314

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	389	1,202	$169,734
2016	507	1,497	$143,405
2017	529	1,624	$148,094
2018	669	1,959	$194,539
2019	625	2,024	$178,391
2020	781	2,345	$194,104
2021	809	2,408	$219,982
2022	954	2,742	$257,808
2023	1,338	3,825	$315,592
2024	1,481	4,068	$284,437

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	358	529	$107
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	144	366	$104
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	135	279	$69
94729	Test to examine how well the lungs exchange gases	108	112	$50
94727	Test to determine lung volumes using gas dilution or washout	99	103	$40

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	428	15,480	$326,715
Dupixent Pen	Dupilumab	62	1,862	$259,905
Ofev	Nintedanib Esylate	24	720	$249,989
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	136	4,920	$101,230
Breo Ellipta	Fluticasone/Vilanterol	152	6,660	$83,608

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	70	$53,246
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	N/R	34	$34,129
E0465	Home ventilator, any type, used with invasive interface, (e.g., tracheostomy tube)	Y	N/R	14	$26,360
A7030	Full face mask used with positive airway pressure device, each	N	101	237	$18,479
A7031	Face mask interface, replacement for full face mask, each	N	97	235	$17,388

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	91	$1,714	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Aaron David Crookshank, MD?

Tedicare shows public-source Medicare data for Aaron David Crookshank, MD (NPI 1285875633), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Aaron David Crookshank, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Aaron David Crookshank, MD?

Aaron David Crookshank, MD is linked to VIRTUA MEDICAL GROUP, PA (billing NPI 1649226515) in the available physician profile data.

Does Aaron David Crookshank, MD have Open Payments data?

Aaron David Crookshank, MD has 91 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.